Seven weeks after Pfizer's main Lipitor patent expired in the US, the drug is down to 32% market share and at least one name-brand analyst is casting doubt on the brand's survival strategy.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.